Merck & Co Q2 2024 Adj. EPS $2.28 Beats $2.15 Estimate, Sales $16.112B Beat $15.841B Estimate
Portfolio Pulse from Benzinga Newsdesk
Merck & Co reported Q2 2024 adjusted EPS of $2.28, beating the estimate of $2.15. Sales were $16.112 billion, surpassing the estimate of $15.841 billion.
July 30, 2024 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck & Co reported better-than-expected Q2 2024 results with an adjusted EPS of $2.28 and sales of $16.112 billion, both surpassing analyst estimates.
Merck & Co's Q2 2024 earnings and sales both exceeded analyst expectations, which is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100